Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC

Clinical trial NCT06102395 · RECRUITING

Trial details

NCT number: NCT06102395
Sponsor: Beijing Tongren Hospital
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma Neoadjuvant Therapy Pembrolizumab

Start date: 2023-05-01
Primary completion: 2027-04-30
Enrollment: 272

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.